David Phillips has over 30 years of experience in the global healthcare industry, including 14 years in sales and marketing with Glaxo Wellcome, Cephalon, Oxford Molecular Group, and eight years with SR One (GlaxoSmithKline’s corporate venture fund).
Mr Phillips also spent 12 years at board level as chief business officer of Argenta Discovery, The Automation Partnership and BioFocus. He re-joined GlaxoSmithKline’s (GSK) SR One corporate venture arm in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early-stage life science companies. Mr Phillips has been involved in the monetisation of a number of R&D operations and drug delivery technologies, including leading the team that divested GSK’s opiates business in Australia in 2015.
Mr Phillips was a senior investment manager at BioScience Managers, a leading life sciences investment firm.